Impax Laboratories Inc (IPXL)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014230)
◆英語タイトル:Impax Laboratories Inc (IPXL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014230
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:64
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous system (CNS) disorders and other select specialties. The company also has few product candidates in varying stages of development. Impax developed several controlled-release delivery technologies which can be utilized with a variety of oral dosage forms and drugs. It has manufacturing facilities in Hayward, California; Middlesex, New Jersey; and in Taiwan. The company sells its products directly to wholesalers and large retail drug chains and through unrelated third-party pharmaceutical entities. Impax is headquartered in Hayward, California, the US.

Impax Laboratories Inc (IPXL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 12
Impax Labs Acquires Two Generic Products from Actavis 14
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 15
Partnerships 16
Impax Labs Enters Into Co-Development Agreement With Perrigo 16
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 17
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 18
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 19
Merger 20
Amneal and Impax to Merge 20
Licensing Agreements 23
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 23
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 25
Debt Offering 27
Impax Labs Raises USD600 Million in Private Placement of 2% Notes Due 2022 27
Asset Transactions 29
Turing Pharma Acquires Daraprim Marketing Rights in US from Impax Lab for USD55 Million 29
Acquisition 30
Impax Acquires Lineage Therapeutics, Amedra Pharma and CorePharma for USD700 Million 30
Impax Laboratories Inc – Key Competitors 32
Impax Laboratories Inc – Key Employees 33
Impax Laboratories Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Financial Announcements 36
Nov 09, 2017: Impax Reports Third Quarter 2017 Results 36
Aug 09, 2017: Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million 39
May 10, 2017: Impax Reports First Quarter 2017 Financial Results 41
Mar 01, 2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results 44
Nov 09, 2016: Impax Reports Third Quarter 2016 Financial Results 47
Aug 09, 2016: Impax Reports Second Quarter 2016 Financial Results 49
May 10, 2016: Impax Reports First Quarter 2016 Financial Results 52
Feb 22, 2016: Impax Reports Fourth Quarter and Full Year 2015 Financial Results 54
Corporate Communications 57
Nov 08, 2017: Impax Laboratories Mourns the Passing of Board Member Richard A. Bierly 57
Mar 27, 2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO 58
Dec 20, 2016: Impax Laboratories Announces Leadership Transition 59
Nov 28, 2016: Impax Laboratories appoints new board member 60
Aug 22, 2016: Richard A. Bierly Appointed to Impax Laboratories Board of Directors 61
Apr 14, 2016: Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and Michael Markbreiter from its Board of Directors 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Impax Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Impax Laboratories Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 12
Impax Labs Acquires Two Generic Products from Actavis 14
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 15
Impax Labs Enters Into Co-Development Agreement With Perrigo 16
Impax Labs Enters Into Development And Distribution Agreement With Tolmar 17
IMPAX Lab Enters Into Co-Development Agreement With TOLMAR 18
IMPAX Labs Enters Into Co-Marketing Agreement With Banner Pharmacaps 19
Amneal and Impax to Merge 20
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 23
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 25
Impax Labs Raises USD600 Million in Private Placement of 2% Notes Due 2022 27
Turing Pharma Acquires Daraprim Marketing Rights in US from Impax Lab for USD55 Million 29
Impax Acquires Lineage Therapeutics, Amedra Pharma and CorePharma for USD700 Million 30
Impax Laboratories Inc, Key Competitors 32
Impax Laboratories Inc, Key Employees 33
Impax Laboratories Inc, Other Locations 34
Impax Laboratories Inc, Subsidiaries 34

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Impax Laboratories Inc (IPXL)-製薬・医療分野:企業M&A・提携分析(Impax Laboratories Inc (IPXL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆